AC Immune’s (ACIU) “Buy” Rating Reiterated at BTIG Research

BTIG Research reaffirmed their buy rating on shares of AC Immune (NASDAQ:ACIU) in a research note released on Thursday,Benzinga reports. BTIG Research currently has a $8.00 price target on the stock.

Other equities research analysts also recently issued research reports about the stock. HC Wainwright reissued a “buy” rating on shares of AC Immune in a research report on Wednesday, July 1st. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of AC Immune in a research report on Wednesday, August 5th. Three investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company has an average rating of “Hold” and an average price target of $7.50.

AC Immune Price Performance

Shares of ACIU opened at $2.90 on Thursday. The company has a debt-to-equity ratio of 0.11, a quick ratio of 1.02 and a current ratio of 0.93. The stock has a 50 day simple moving average of $2.42 and a 200 day simple moving average of $2.70. AC Immune has a 52-week low of $2.03 and a 52-week high of $4.00. The firm has a market capitalization of $295.13 million, a PE ratio of -5.37 and a beta of 1.59.

AC Immune (NASDAQ:ACIU) last posted its earnings results on Thursday, August 6th. The company reported $0.03 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.10) by $0.13. AC Immune had a negative return on equity of 100.17% and a negative net margin of 245.32%.The business had revenue of $18.67 million during the quarter, compared to analysts’ expectations of $9.59 million. Sell-side analysts predict that AC Immune will post -0.6 EPS for the current fiscal year.

Hedge Funds Weigh In On AC Immune

Large investors have recently bought and sold shares of the company. Acadian Asset Management LLC grew its stake in shares of AC Immune by 87.1% during the 1st quarter. Acadian Asset Management LLC now owns 371,177 shares of the company’s stock worth $679,000 after acquiring an additional 172,796 shares in the last quarter. Sei Investments Co. acquired a new position in AC Immune during the second quarter worth $51,000. Private Advisor Group LLC acquired a new position in AC Immune during the third quarter worth $48,000. Susquehanna International Group LLP acquired a new position in AC Immune during the third quarter worth $63,000. Finally, Goldman Sachs Group Inc. grew its position in AC Immune by 46.9% in the fourth quarter. Goldman Sachs Group Inc. now owns 18,555 shares of the company’s stock valued at $58,000 after purchasing an additional 5,920 shares in the last quarter. Institutional investors and hedge funds own 51.36% of the company’s stock.

AC Immune Company Profile

AC Immune AG is a clinical-stage biopharmaceutical company headquartered in Lausanne, Switzerland, with a subsidiary in Boston, Massachusetts. The company specializes in the discovery and development of therapeutics and diagnostics for neurodegenerative diseases, with a primary focus on Alzheimer’s disease, Parkinson’s disease and other protein misfolding disorders. AC Immune leverages proprietary platform technologies to identify and optimize candidates that target pathological protein aggregates.

Since its founding in 2003, AC Immune has advanced multiple programs into clinical development.